DOCSLIB.ORG

1 Cxcr3 and Αeβ7 Integrin Identify a Subset of Cd8+

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Cxcr3 and Αeβ7 Integrin Identify a Subset of Cd8+ Gut Online First, published on December 20, 2005 as 10.1136/gut.2005.077560 1 Gut: first published as 10.1136/gut.2005.077560 on 20 December 2005. Downloaded from CXCR3 AND αEβ7 INTEGRIN IDENTIFY A SUBSET OF CD8+ MATURE THYMOCYTES THAT SHARE PHENOTYPIC AND FUNCTIONAL PROPERTIES WITH CD8+ GUT INTRAEPITHELIAL LYMPHOCYTES. Corresponding author: Sergio Romagnani, Dipartimento di Medicina Interna, Università di Firenze, Viale Morgagni 85, Firenze 50134 Italy; e-mail: [email protected] FRANCESCO ANNUNZIATO,* LORENZO COSMI,* FRANCESCO LIOTTA,* ELENA LAZZERI,* PAOLA ROMAGNANI,* ROBERTA ANGELI,* LAURA LASAGNI,* ROBERTO MANETTI,* FABIO MARRA,* CRAIG GERARD,‡ ILARIA PETRAI,* PERSIO DELLO SBARBA,§ FRANCESCO TONELLI,* ENRICO MAGGI,* AND SERGIO ROMAGNANI* * Center for Research, Transfer and High Education “DENOthe”, University of Florence, Florence, Italy.‡ Ina Sue Perlmutter Laboratory, Children Hospital, Harvard Medical School, Boston, MA; § Department of Experimental Pathology and Oncology University of Florence, Italy. Keywords: Thymus, Gut Mucosa, T Lymphocytes, Cell Trafficking, Chemokine Receptors Abbreviations: SP, single-positive; PB, peripheral blood; IELs, intraepithelial lymphocytes; HEV, high endothelial venules; mAbs, monoclonal antibodies; FCS, fetal calf serum; LNs, lymph nodes The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article to be published in Gut editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://gut.bmjjournals.com/misc/ifora/licenceform.shtml)." http://gut.bmj.com/ on September 23, 2021 by guest. Protected copyright. Copyright Article author (or their employer) 2005. Produced by BMJ Publishing Group Ltd (& BSG) under licence. 2 Gut: first published as 10.1136/gut.2005.077560 on 20 December 2005. Downloaded from ABSTRACT Background: We previously demonstrated the existence in human post-natal thymus of two distinct subsets of TCRαβ+CD8αβ+ single-positive (SP) cells which express the chemokine receptor CCR7 or CXCR3 and migrate in vitro in response to their specific ligands. Aim: To investigate whether these two CD8+ thymocyte subsets had distinct peripheral colonization. Methods: TCRαβ+CD8+ SP cells were obtained from normal postnatal thymus, mesenteric lymph node (LNs), small bowel and peripheral blood (PB) specimens. Cells were then evaluated for expression of surface molecules, cytolitic potential, telomere length and profile of cytokine production. Results: CD8+CCR7+CXCR3- thymocytes exhibited CD62L, as those which localize to LNs. By contrast, CD8+CCR7-CXCR3+ thymocytes lacked CD62L, but exhibited CD103 as intraepithelial lymphocytes (IELs) present in the gut mucosa, where the CXCR3 ligand, CXCL10, and the CD103 ligand, E-cadherin, are highly and consistently expressed. In addition, thymocytes and gut CD8+CXCR3+CD103+ cells showed comparable telomere length, which was higher than that of PB CXCR3+CD8+ T cells. However, both these populations contained perforin and granzyme A, and displayed the ability to produce IFN-γ and IL-2. Of note, CXCR3-deficient, in comparison with wild-type C57Black/6, mice showed decreased proportions of CD3+CD8αβ+, and increased proportions of CD3+CD8αα+, lymphocytes at gut level. Moreover, adoptive transfer of CD3+CD8αβ+ thymocytes from wild-type into CXCR3-deficient mice resulted in a significant increase of CD3+CD8αβ+ T cells in the gut mucosa, but not in other tissues. Conclusions: The results of this study demonstrate the existence of a previous unrecognized subset of TCRαβ+CD8αβ+ SP CXCR3+CD103+ thymocytes, which share phenotypic and functional features with CD8+ IELs, thus suggesting the possibility of their direct colonization to the gut mucosa. http://gut.bmj.com/ on September 23, 2021 by guest. Protected copyright. 3 Gut: first published as 10.1136/gut.2005.077560 on 20 December 2005. Downloaded from INTRODUCTION Chemokines and their receptors play an essential role in the trafficking of lymphocytes during their development into primary lymphoid organs [1], their migration to peripheral lymphoid organs [2], and their recruitment into the inflamed tissues as a consequence of antigen activation [3]. Recirculating lymphocytes are recruited from the blood stream into lymphoid tissues via selective interactions with high endothelial venules (HEV). Lymphocyte recognition of HEV involves a multistep adhesion cascade in which different selectins, chemokines, and integrins participate in the primary adhesive interactions, as well as in the firm arrest. There is convincing evidence to suggest that the chemokines CCL19 and CCL21, and their specific receptor, CCR7, expressed on naïve T lymphocytes, are involved this process [4] [5] [6] [7]. Indeed, mice deficient in CCL21 and CCL19 production have severe defects in T-cell homing to peripheral lymphoid organs, as mice with targeted deletion of CCR7 do [8][9][10]. The presence of CCL21 and CCL19 has also been demonstrated in murine and human thymus, where these chemokines exert chemotactic activity on both mature SP CD4+ and CD8+ thymocytes, thus favouring their migration into the circulation [11] [12]. Besides CCR7, circulating naïve T cells are known to express only two other chemokine receptors, CCR9 (expressed by a small subset of naïve T cells) and CXCR4 (broadly expressed), both of which also bind homeostatic chemokines. Thus far, a role for CCR9 in the entry of T cells into LNs has not been demonstrated. The ligand for CCR9 is CCL25, which is selectively expressed in the small intestine [13][14], raising the possibility that this chemokine is involved in the traffic of naïve CCR9+ T cells to lymphoid structures of the small intestine. However, it is also possible that the presence in CCR9 by naïve T cells is simply a remnant of development in the thymus, as CCR9 is broadly expressed by thymocytes [13][15]. By contrast, CXCR4 does appear to contribute to T cell entry into LNs. Indeed, CXCL12 (the ligand for CXCR4) has been shown to promote transendothelial migration of T cells across the HEVs [16]. Hence, CCR7 and CXCR4 may co- operate in the task of naïve T cell recruitment into LNs. Of note, other chemokine receptors with expression on naïve T cells have not yet been identified. CXCR3 binds the chemokines CXCL10, CXCL9, and CXCL11, is expressed on the surface of different cell types, including activated T cells http://gut.bmj.com/ and NK cells, and subsets of inflammatory dendritic cells, macrophages, and B cells and its expression on T lymphocytes is upregulated by inflammation (3). Recently, we discovered the presence in human post-natal thymus of a subset of TCRαβ+CD8αβ+ SP cells which express CXCR3 and migrate in vitro in response to CXCL10, CXCL9, and CXCL11, but not to CCL19 or CCL21 [17]. Thymic TCRγδ and CD3-CD56+ (NK-like) cells also showed a similar behaviour [17]. In this study, we hypothesized that the two CD8+ thymocyte subsets (CCR7+ or CXCR3+) on September 23, 2021 by guest. Protected copyright. had distinct peripheral colonization. Therefore, we assessed the presence of CCR7 and CXCR3, as well as of other phenotypic and functional markers, in TCRαβ+CD8αβ+ SP thymocytes and compared the phenotype of these cells with that of CD8αβ+ T cells present in different tissues, such as lymph nodes, PB and small bowel. The results showed that SP CD8+ thymocytes expressing CXCR3 represent a distinct population of cells that selectively colonize to the lymphoid structures of the small intestine. MATERIAL AND METHODS Human specimens Normal postnatal thymus specimens were obtained from 11 children, aged between 5 days and 3 years, and from one 42 year-old male, who underwent corrective cardiac surgery. Normal mesenteric LNs, uninvolved small bowel specimens, and PB lymphocytes were all obtained from 18 patients, who underwent surgery because of colon cancer (8 patients) or Crohn’s disease (10 patients). Additional PB samples were obtained from 13 healthy volunteers. All the patients gave their informed consent. The procedures followed in the study were in accordance with the ethical standards of the Regional Committee on Human Experimentation that gave their approval. 4 Gut: first published as 10.1136/gut.2005.077560 on 20 December 2005. Downloaded from Animals CXCR3 deficient mice backcrossed 10 generations into the C57Black/6 background have been previously described [18]. Wild-type C57Black/6 mice were used as controls. Mice were maintained in specific pathogen-free conditions environment until use. Reagents Purified anti-CD8α, as well as, the fluorocrome-conjugated anti-CD3, anti-CD4, anti-CD62L, anti- CD103, anti-CD20, anti-TCRγδ, anti-IL-2, anti-IL-4, anti-IL-10, anti-IL-13, anti-IFN-γ, anti- perforin and anti-granzyme A monoclonal antibodies (mAbs) were purchased from Becton Dickinson (San Jose, CA); anti-CD8β and anti-E-cadherin mAbs were obtained by Beckman Coulter (Brea, CA). The goat anti-mouse IgG Abs conjugated with magnetic beads were obtained from Miltenyi Biotec (Bisley, Germany). Purified, fluorocrome-conjugated isotype control and fluorocrome-conjugated anti-isotype mAbs were purchased from Southern Biotechnology Associates (Birmingham, AL). The purified and PE-conjugated anti-CXCR3, anti-CCR9 and anti- CCR7 mAbs were obtained by R & D (Minneapolis, MN). Anti-CXCL10 rabbit polyclonal Ab was from Peprotech (London, UK). Fluorochrome-conjugated
Load more

Recommended publications
  • Enhanced Monocyte Migration to CXCR3 and CCR5 Chemokines in COPD
    ERJ Express. Published on March 10, 2016 as doi: 10.1183/13993003.01642-2015 ORIGINAL ARTICLE IN PRESS | CORRECTED PROOF Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD Claudia Costa1, Suzanne L. Traves1, Susan J. Tudhope1, Peter S. Fenwick1, Kylie B.R. Belchamber1, Richard E.K. Russell2, Peter J. Barnes1 and Louise E. Donnelly1 Affiliations: 1Airway Disease, National Heart and Lung Institute, Imperial College London, London, UK. 2Chest Clinic, King Edward King VII Hospital, Windsor, UK. Correspondence: Louise E. Donnelly, Airway Disease, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK. E-mail: [email protected] ABSTRACT Chronic obstructive pulmonary disease (COPD) patients exhibit chronic inflammation, both in the lung parenchyma and the airways, which is characterised by an increased infiltration of macrophages and T-lymphocytes, particularly CD8+ cells. Both cell types can express chemokine (C-X-C motif) receptor (CXCR)3 and C-C chemokine receptor 5 and the relevant chemokines for these receptors are elevated in COPD. The aim of this study was to compare chemotactic responses of lymphocytes and monocytes of nonsmokers, smokers and COPD patients towards CXCR3 ligands and chemokine (C-C motif) ligand (CCL)5. Migration of peripheral blood mononuclear cells, monocytes and lymphocytes from nonsmokers, smokers and COPD patients toward CXCR3 chemokines and CCL5 was analysed using chemotaxis assays. There was increased migration of peripheral blood mononuclear cells from COPD patients towards all chemokines studied when compared with nonsmokers and smokers. Both lymphocytes and monocytes contributed to this enhanced response, which was not explained by increased receptor expression.
    [Show full text]
  • Cytokines (CCL25)
    Mouse Recombinant TECK Cytokines (CCL25) Thymus-expressed chemokine Catalog # 78180 5 μg 78180.1 25 μg Product Description Thymus-expressed chemokine (TECK), or CCL25, is a member of the CC family of chemokines that regulates the movement of lymphocytes in the thymus and in the small intestine. TECK induces chemoattraction by binding the chemokine receptor CCR9, which is expressed on immature pre-T cells and thymocytes (Youn et al.; Uehara et al.). In the thymus, TECK is produced by stromal cells, whereas in the small intestine TECK is primarily produced by epithelial cells (Vicari et al.; Bowman et al.; Kunkel et al.). CCR9 is a G protein-coupled receptor and is expressed on most thymocytes, but not on natural killer cells, monocytes, eosinophils, basophils, and neutrophils (Wu et al). In Jurkat cells, binding of TECK to CCL9 has been shown to increase levels of intracellular calcium (Cheng-Rong et al). TECK/CCR9 signaling has also been linked to many cancers, as these molecules have been shown to mediate anti-apoptotic processes by activating the PI3K/AKT signaling pathway, weakening the effect of cytotoxic T cells by regulating STAT signaling. Additionally, TECK induces metastasis by increasing the expression of MMP2 and MMP9 (Tu et al.). Product Information Alternative Names: C-C motif chemokine 25, CCL25, Chemokine TECK, Ckb15, MGC150327, SCYA25, Small-inducible cytokine A25, Thymus-expressed chemokine Accession Number: O35903 Amino Acid Sequence: MQGAFEDCCL GYQHRIKWNV LRHARNYHQQ EVSGSCNLRA VRFYFRQKVV CGNPEDMNVK RAMRILTARK RLVHWKSASD SQTERKKSNH MKSKVENPNS TSVRSATLGH PRMVMMPRKT NN Predicted Molecular Mass: 14.3 kDa Species: Mouse Cross Reactivity: Reported to be species-specific Formulation: Lyophilized after dialysis against phosphate-buffered saline.
    [Show full text]
  • IL-2 and IL-12 Alter NK Cell Responsiveness to IFN- Γ-Inducible Protein 10 by Down-Regulating CXCR3 Expression
    IL-2 and IL-12 Alter NK Cell Responsiveness to IFN- γ-Inducible Protein 10 by Down-Regulating CXCR3 Expression This information is current as Deborah L. Hodge, William B. Schill, Ji Ming Wang, Isaac of September 29, 2021. Blanca, Della A. Reynolds, John R. Ortaldo and Howard A. Young J Immunol 2002; 168:6090-6098; ; doi: 10.4049/jimmunol.168.12.6090 http://www.jimmunol.org/content/168/12/6090 Downloaded from References This article cites 37 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/168/12/6090.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IL-2 and IL-12 Alter NK Cell Responsiveness to IFN-␥-Inducible Protein 10 by Down-Regulating CXCR3 Expression1 Deborah L. Hodge,* William B.
    [Show full text]
  • Memory T Lymphocyte Activation'' Desensitization of CXCL12
    Comment on ''CXCL9 Causes Heterologous Desensitization of CXCL12-Mediated Memory T Lymphocyte Activation'' This information is current as Graeme O'Boyle, Simi Ali and John A. Kirby of October 1, 2021. J Immunol 2013; 191:525; ; doi: 10.4049/jimmunol.1390036 http://www.jimmunol.org/content/191/2/525.1 Downloaded from References This article cites 6 articles, 2 of which you can access for free at: http://www.jimmunol.org/content/191/2/525.1.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 1, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Th eJournal of Letters to the Editor Immunology receptor CXCR3 agonist prevents human T-cell migration in a humanized model Comment on “CXCL9 Causes of arthritic inflammation. Proc. Natl. Acad. Sci. USA 109: 4598–4603. Heterologous Desensitization of 5. Nedjai, B., H. Li, I. L.
    [Show full text]
  • Chemokine Receptor CXCR3 Promotes Colon Cancer Metastasis to Lymph Nodes
    Oncogene (2007) 26, 4679–4688 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc ORIGINAL ARTICLE Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes K Kawada1,2,5, H Hosogi1,2,5, M Sonoshita1, H Sakashita3, T Manabe3, Y Shimahara2, Y Sakai2, A Takabayashi4, M Oshima1 and MM Taketo1 1Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 2Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 3Department of Clinical Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Japan and 4Kitano Hospital Medical Institute, Osaka, Japan Chemokines and their receptors are essential for leuko- inflammatory cytokines, growth factors and/or patho- cyte trafficking, and also implicated in cancer metastasis genic stimuli. Important roles of chemokines and their to specific organs. We have recently demonstrated that receptors have been demonstrated in inflammation, CXCR3 plays a critical role in metastasis of mouse infection, tissue injury, allergy and cardiovascular melanoma cells to lymph nodes. Here, we show that some diseases as well as in malignant tumors. Chemokine human colon cancer cell lines express CXCR3 constitu- receptor CXCR3 is essential for the physiologic and tively. We constructed cells that expressed CXCR3 cDNA pathologic recruitment of plasmacytoid dendritic cell (‘DLD-1-CXCR3’), and compared with nonexpressing precursors, monocytes and natural killer cells to controls by rectal transplantation in nude mice. Although inflamed lymph nodes (LNs) (Cella et al., 1999; both cell lines disseminated to lymph nodes at similar Janatpour et al., 2001; Martin-Fontecha et al., 2004), frequencies at 2 weeks, DLD-1-CXCR3 expanded more and for retention of Th1 lymphocytes within LNs rapidly than the control in 4 weeks.
    [Show full text]
  • Responses in Rhesus Macaques CD4 T Cell − and CXCR5 + CXCR5
    Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5− CD4 T Cell Responses in Rhesus Macaques This information is current as of September 27, 2021. Smita S. Iyer, Sailaja Gangadhara, Blandine Victor, Rosy Gomez, Rahul Basu, Jung Joo Hong, Celia Labranche, David C. Montefiori, Francois Villinger, Bernard Moss and Rama Rao Amara J Immunol 2015; 195:994-1005; Prepublished online 26 June Downloaded from 2015; doi: 10.4049/jimmunol.1500083 http://www.jimmunol.org/content/195/3/994 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2015/06/26/jimmunol.150008 Material 3.DCSupplemental References This article cites 33 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/195/3/994.full#ref-list-1 by guest on September 27, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • CXCR6 Within T-Helper (Th) and T-Cytotoxic
    European Journal of Endocrinology (2005) 152 635–643 ISSN 0804-4643 EXPERIMENTAL STUDY CXCR6 within T-helper (Th) and T-cytotoxic (Tc) type 1 lymphocytes in Graves’ disease (GD) G Aust, M Kamprad1, P Lamesch2 and E Schmu¨cking Institute of Anatomy, 1Department of Clinical Immunology and Transfusion Medicine and 2Department of Surgery, University of Leipzig, Phillipp-Rosenthal-Str. 55, Leipzig, 04103, Germany (Correspondence should be addressed to G Aust; Email: [email protected]) Abstract Objective: In Graves’ disease (GD), stimulating anti-TSH receptor antibodies are responsible for hyperthyroidism. T-helper 2 (Th2) cells were expected to be involved in the underlying immune mech- anism, although this is still controversial. The aim of this study was to examine the expression of CXCR6, a chemokine receptor that marks functionally specialized T-cells within the Th1 and T-cyto- toxic 1 (Tc1) cell pool, to gain new insights into the running immune processes. Methods: CXCR6 expression was examined on peripheral blood lymphocytes (PBLs) and thyroid- derived lymphocytes (TLs) of GD patients in flow cytometry. CXCR6 cDNA was quantified in thyroid tissues affected by GD (n ¼ 16), Hashimoto’s thyroiditis (HT; n ¼ 2) and thyroid autonomy (TA; n ¼ 11) using real-time reverse transcriptase PCR. Results: The percentages of peripheral CXCR6þ PBLs did not differ between GD and normal subjects. CXCR6 was expressed by small subsets of circulating T-cells and natural killer (NK) cells. CXCR6þ cells were enriched in thyroid-derived T-cells compared with peripheral CD4þ and CD8þ T-cells in GD. The increase was evident within the Th1 (CD4þ interferon-gþ (IFN-gþ)) and Tc1 (CD8þIFN- gþ) subpopulation and CD8þ granzyme Aþ T-cells (cytotoxic effector type).
    [Show full text]
  • Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3+ Regulatory T Cells
    Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3+ Regulatory T Cells This information is current as Hyung W. Lim, Jeeho Lee, Peter Hillsamer and Chang H. of September 28, 2021. Kim J Immunol 2008; 180:122-129; ; doi: 10.4049/jimmunol.180.1.122 http://www.jimmunol.org/content/180/1/122 Downloaded from References This article cites 44 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/180/1/122.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3؉ Regulatory T Cells1 Hyung W. Lim,* Jeeho Lee,* Peter Hillsamer,† and Chang H. Kim2* It is a question of interest whether Th17 cells express trafficking receptors unique to this Th cell lineage and migrate specifically to certain tissue sites.
    [Show full text]
  • CXCR6 Deficiency Impairs Cancer Vaccine Efficacy and CD8+ Resident Memory T-­Cell Recruitment in Head and Neck and Lung Tumors
    Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-001948 on 10 March 2021. Downloaded from CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T- cell recruitment in head and neck and lung tumors Soumaya Karaki,1,2 Charlotte Blanc,1,2 Thi Tran,1,2 Isabelle Galy- Fauroux,1,2 Alice Mougel,1,2 Estelle Dransart,3 Marie Anson,1,2 Corinne Tanchot,1,2 Lea Paolini,1,2 Nadege Gruel,4,5 Laure Gibault,6 Francoise Lepimpec- Barhes,7 Elizabeth Fabre,8 Nadine Benhamouda,9 Cecile Badoual,6 Diane Damotte,10 11 12,13 14 Emmanuel Donnadieu , Sebastian Kobold, Fathia Mami- Chouaib, 15 3 1,2,9 Rachel Golub, Ludger Johannes, Eric Tartour To cite: Karaki S, Blanc C, ABSTRACT explains why the intranasal route of vaccination is the Tran T, et al. CXCR6 deficiency most appropriate strategy for inducing these cells in the Background Resident memory T lymphocytes (TRM) impairs cancer vaccine efficacy are located in tissues and play an important role in head and neck and pulmonary mucosa, which remains a and CD8+ resident memory immunosurveillance against tumors. The presence of T major objective to overcome resistance to anti- PD-1/PD- T- cell recruitment in head and RM prior to treatment or their induction is associated to the L1, especially in cold tumors. neck and lung tumors. Journal for ImmunoTherapy of Cancer response to anti- Programmed cell death protein 1 (PD- 2021;9:e001948. doi:10.1136/ 1)/Programmed death- ligand 1 (PD- L1) immunotherapy jitc-2020-001948 and the efficacy of cancer vaccines.
    [Show full text]
  • Functional Redundancy of CXCR3/CXCL10 Signaling in the Recruitment
    Page 1 of 32 Diabetes Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic CTL to pancreatic islets in a virally induced autoimmune diabetes model Ken T. Coppieters*,§, Natalie Amirian*, Philippe P. Pagni*, Carmen Baca Jones*, Anna Wiberg*, Stanley Lasch#, Edith Hintermann#, Urs Christen# and Matthias G. von Herrath*,§ *Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla CA 92037, U.S.A. §Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, U.S.A. #Pharmazentrum Frankfurt / ZAFES, Goethe University Hospital, Frankfurt am Main, Germany Short title: CXCR3/CXCL10 signaling in type 1 diabetes Correspondence: Matthias von Herrath, Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla CA 92037, U.S.A., [email protected], Phone: (858) 752-6817; Fax: (858) 752-6993 1 Diabetes Publish Ahead of Print, published online February 22, 2013 Diabetes Page 2 of 32 Abstract Cytotoxic T lymphocytes (CTL) constitute a major effector population in pancreatic islets from patients suffering from type 1 diabetes (T1D) and thus represent attractive targets for intervention. Some studies have suggested that blocking the interaction between the chemokine CXCL10 and its receptor CXCR3 on activated CTL potently inhibits their recruitment and prevents beta cell death. Since recent studies on human pancreata from T1D patients have indicated that both ligand and receptor are abundantly present, we reevaluated whether their interaction constitutes a pivotal node within the chemokine network associated with T1D. Our present data in a viral mouse model challenge the notion that specific blockade of the CXCL10/CXCR3 chemokine axis halts T1D onset and progression.
    [Show full text]
  • Role of CXCR3 Ligands in IL-7/IL-7Ra-Fc–Mediated Antitumor Activity in Lung Cancer
    Clinical Cancer Cancer Therapy: Preclinical Research Role of CXCR3 Ligands in IL-7/IL-7Ra-Fc–Mediated Antitumor Activity in Lung Cancer Asa Andersson1, Minu K. Srivastava1, Marni Harris-White3,4, Min Huang1,2,4, Li Zhu1,2,4, David Elashoff1, Robert M. Strieter5, Steven M. Dubinett1,2,4, and Sherven Sharma1,2,4 Abstract Purpose: We evaluated the utility of chimeric gc homeostatic cytokine, IL-7/IL-7Ra-Fc, to restore host APC (antigen presenting cell) and T cell activities in lung cancer. Experimental Design: Utilizing murine lung cancer models we determined the antitumor efficacy of IL- 7/IL-7Ra-Fc. APC, T cell, cytokine analyses, neutralization of CXCL9, CXCL10, and IFNg were carried out to evaluate the mechanistic differences in the antitumor activity of IL-7/IL-7Ra-Fc in comparison to controls. Results: IL-7/IL-7Ra-Fc administration inhibited tumor growth and increased survival in lung cancer. Accompanying the tumor growth inhibition were increases in APC and T cell activities. In comparison to controls, IL-7/IL-7Ra-Fc treatment of tumor bearing mice led to increased: (i) levels of CXCL9, CXCL10, IFNg, IL-12 but reduced IL-10 and TGFb, (ii) tumor macrophage infiltrates characteristic of M1 phenotype with increased IL-12, iNOS but reduced IL-10 and arginase, (iii) frequencies of T and NK cells, (iv) T cell activation markers CXCR3, CD69 and CD127low, (v) effector memory T cells, and (vi) T cell cytolytic activity against parental tumor cells. IL-7/IL-7Ra-Fc treatment abrogated the tumor induced reduction in splenic functional APC activity to T responder cells.
    [Show full text]
  • Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
    cancers Review Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them? Justine Cinier 1,†, Margaux Hubert 1,†, Laurie Besson 1, Anthony Di Roio 1 ,Céline Rodriguez 1, Vincent Lombardi 2, Christophe Caux 1,‡ and Christine Ménétrier-Caux 1,*,‡ 1 University of Lyon, Claude Bernard Lyon 1 University, INSERM U-1052, CNRS 5286 Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; [email protected] (J.C.); [email protected] (M.H.); [email protected] (L.B.); [email protected] (A.D.R.); [email protected] (C.R.); [email protected] (C.C.) 2 Institut de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France; [email protected] * Correspondence: [email protected] † Co-first authorship. ‡ Co-last authorship. Simple Summary: The immune response against cancer is generated by effector T cells, among them cytotoxic CD8+ T cells that destroy cancer cells and helper CD4+ T cells that mediate and support the immune response. This antitumor function of T cells is tightly regulated by a particular subset of CD4+ T cells, named regulatory T cells (Tregs), through different mechanisms. Even if the complete inhibition of Tregs would be extremely harmful due to their tolerogenic role in impeding autoimmune diseases in the periphery, the targeted blockade of their accumulation at tumor sites or their targeted Citation: Cinier, J.; Hubert, M.; depletion represent a major therapeutic challenge. This review focuses on the mechanisms favoring Besson, L.; Di Roio, A.; Rodriguez, C.; Treg recruitment, expansion and stabilization in the tumor microenvironment and the therapeutic Lombardi, V.; Caux, C.; strategies developed to block these mechanisms.
    [Show full text]